ArticleBMJ open2025

Cost-effectiveness analysis of enfortumab vedotin and pembrolizumab versus chemotherapy for patients with untreated advanced urothelial cancer in the United Kingdom.

Qiuji Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.